You are here

Amylyx

Amylyx’s ALS drug could face rejection in Europe

Amylyx’s ALS drug could face rejection in Europe

BioPharma Dive

Flag link:

3 Biotechs That Might Get Bought Out in 2023

3 Biotechs That Might Get Bought Out in 2023

Motley Fool

Madrigal Pharmaceuticals

Aurinia Pharmaceuticals

Flag link:

Amylyx’s ALS drug sales impress Wall Street

Amylyx’s ALS drug sales impress Wall Street

BioPharma Dive

Flag link:

Amylyx completes subject enrollment in ALS therapy trial

Amylyx completes subject enrollment in ALS therapy trial

Clinical Trials Arena

clinical trials

Flag link:

For ALS patients, doctors, a new medicine reignites concerns about healthcare access

For ALS patients, doctors, a new medicine reignites concerns about healthcare access

BioPharma Dive

Flag link:

FDA seems poised to approve a new drug for ALS, but does it work?

FDA seems poised to approve a new drug for ALS, but does it work?

NPR

Flag link:

Highlighted by Amylyx, the ALS Space is Gaining Momentum

Highlighted by Amylyx, the ALS Space is Gaining Momentum

BioSpace

NeuroSense Therapeutics

BrainStorm Cell Therapeutics

Flag link:

FDA advisers back Amylyx ALS drug, reversing earlier position

FDA advisers back Amylyx ALS drug, reversing earlier position

BioPharma Dive

Flag link:

FDA Has Ways to Go to Keep Pace with 2020/21 Approvals

FDA Has Ways to Go to Keep Pace with 2020/21 Approvals

BioSpace

Bristol Myers Squibb

Flag link:

FDA to reconvene experts' meeting for Amylyx ALS drug

FDA to reconvene experts' meeting for Amylyx ALS drug

Yahoo/Reuters

Flag link:

Go or no go? The FDA’s Amylyx dilemma

Go or no go? The FDA’s Amylyx dilemma

EP Vantage

Moderna Therapeutics

Flag link:

An FDA panel reviewing Amylyx's ALS drug was moved by patient testimony—but they voted it down anyway

An FDA panel reviewing Amylyx's ALS drug was moved by patient testimony—but they voted it down anyway

Fierce Biotech

Flag link:

Amylyx faces an uphill battle

Amylyx faces an uphill battle

EP Vantage

Flag link:

Amylyx to answer for single-study ALS application at FDA advisory panel

Amylyx to answer for single-study ALS application at FDA advisory panel

Fierce Biotech

clinical trials

Flag link:

As three biotechs head to Wall Street, a battered sector braces for a pullback

As three biotechs head to Wall Street, a battered sector braces for a pullback

BioPharma Dive

Vigil Neuroscience

Flag link:

Amylyx takes its ALS program to Nasdaq, raising the stakes for the biotech's only drug

Amylyx takes its ALS program to Nasdaq, raising the stakes for the biotech's only drug

Endpoints

Flag link:

Amylyx Pharma’s ALS drug needs a Phase 3 study to support FDA submission

Amylyx Pharma’s ALS drug needs a Phase 3 study to support FDA submission

MedCity News

clinical trials

Flag link:

After a rare win, a biotech details long-awaited results for its ALS drug

After a rare win, a biotech details long-awaited results for its ALS drug

BioPharma Dive

Flag link:

Backed by a biotech legend, two young entrepreneurs tackle one of the Holy Grails of R&D

Backed by a biotech legend, two young entrepreneurs tackle one of the Holy Grails of R&D

Endpoints

Lou Gehrig's disease

Flag link: